Literature DB >> 629289

Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer.

P C MacDonald, C D Edman, D L Hemsell, J C Porter, P K Siiteri.   

Abstract

The purpose of this study was to ascertain if a relationship exists between the transfer constant of conversion of plasma androstenedione to estrone ([rho]AE1BU) and total body weight or excessive body weight in 50 postmenopausal women, of whom 25 had adenocarcinoma of the endometrium and 25 had no endometrial disease. The [rho]AE1BU ranged from 0.015 to 0.129 in these 50 women. The [rho]AE1BU in the women with endometrial cancer was 0.051 +/- 0.006 (mean +/- S.E.), whereas that in the women with no endometrial disease was 0.039 +/- 0.004. These values are not significantly different (p greater than 0.05). The body weights of these 50 women ranged from 104 to 430 pounds. The weight of the patients with endometrial cancer was 234 +/- 16 pounds (mean +/- S.E.), and that for the women with no endometrial disease was 194 +/- 12 pounds. A statistically significant correlation (p less than 0.001) was found between [rho]AE1BU and body weight and between [rho]AE1BU and excessive body weight in both groups of women. Moreover, obesity and aging appear to act in concert to potentiate the conversion of plasma androstenedione to estrone in extraglandular sites since the [rho]AE1BU is considerably greater among obese postmenopausal women than among comparably obese premenopausal women.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 629289     DOI: 10.1016/0002-9378(78)90287-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  52 in total

1.  Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study.

Authors:  Divya Seth; Hans Garmo; Annette Wigertz; Lars Holmberg; Niklas Hammar; Ingmar Jungner; Mats Lambe; Göran Walldius; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Carlo Floris; Daniela Massa; Giorgio Astara; Paola Chessa; Giovanni Mantovani
Journal:  J Mol Med (Berl)       Date:  2010-03-26       Impact factor: 4.599

3.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

Review 4.  Ethnic variation in breast cancer survival: a review.

Authors:  L Le Marchand
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

5.  Lifestyle factors and the risk of a second breast cancer after ductal carcinoma in situ.

Authors:  Vicki Hart McLaughlin; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Brian L Sprague
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-08       Impact factor: 4.254

Review 6.  The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity.

Authors:  H Sadie-Van Gijsen; N J Crowther; F S Hough; W F Ferris
Journal:  Cell Mol Life Sci       Date:  2012-11-21       Impact factor: 9.261

7.  Oestrone sulphate, adipose tissue, and breast cancer.

Authors:  R A Hawkins; M L Thomson; E Killen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 8.  Risk factors for osteoporosis and associated fractures.

Authors:  J L Kelsey
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

9.  Long-term postmenopausal hormone therapy and endometrial cancer.

Authors:  Pedram Razavi; Malcolm C Pike; Pamela L Horn-Ross; Claire Templeman; Leslie Bernstein; Giske Ursin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

10.  Dose proportionality and population characteristics of oral fadrozole hydrochloride, an aromatase inhibitor, in postmenopausal women.

Authors:  G M Kochak; R L Choi; E A Entwistle
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.